Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.2
Journals
JPM
Special Issues
Personalized Medicine and Surgery in Cardiovascular Disorders
share announcement

Personalized Medicine and Surgery in Cardiovascular Disorders

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".

Deadline for manuscript submissions: 25 December 2026 | Viewed by 2618

Editors

Dr. Quynh Nguyen

E-Mail
Guest Editor
Division of Cardiac Surgery, Department of Surgery, University of British Columbia, Vancouver, BC V6T 1Z4, Canada
Interests: cardiac surgery; cardiovascular medicine; cardiogenetics; precision medicine
Dr. Edward D. Percy

E-Mail Website
Guest Editor
1. Division of Cardiac Surgery, Department of Surgery, University of British Columbia, Vancouver, BC V6T 1Z4, Canada
2. Vancouver General Hospital, Vancouver, BC V5Z 1M9, Canada
Interests: aortic surgery; coronary surgery; structural heart disease

Special Issue Information

Dear Colleagues,

The expanding role of genetics and personalized therapy is transforming cardiovascular medicine and surgery. Advances in genomics and multi-omics technologies over the last decade have significantly improved our understanding of disease mechanisms, enabling tailored interventions. Recent breakthroughs in gene therapy trials have shown promising results in inherited cardiovascular diseases. At the same time, artificial intelligence (AI) and machine learning are enhancing risk stratification and predictive modeling, leading to more precise treatment strategies. With the heterogeneity of cardiovascular diseases being increasingly recognized, this field is shifting toward targeted, patient-specific approaches.

This Special Issue will explore recent advancements in personalized medicine and surgical approaches in cardiovascular disorders. The integration of genomics, multi-omics, AI, and minimally invasive surgical techniques is enhancing precision medicine in cardiovascular diseases. We aim to highlight innovative research, translational applications, and clinical strategies that can optimize patient outcomes. Topics of interest include the following:

  • Genetic-based risk stratification;
  • Targeted pharmacological treatments;
  • Genomic and multi-omics approaches to cardiovascular diseases;
  • Precision-guided cardiac surgery;
  • Gene therapy for cardiovascular diseases;
  • AI and machine learning in risk prediction models;
  • Virtual and augmented reality in cardiac surgery.

We welcome original research articles, reviews, and other types of paper that contribute to the evolving landscape of cardiovascular precision medicine.

Dr. Quynh Nguyen
Dr. Edward D. Percy
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • precision medicine
  • cardiovascular disorders
  • cardiogenetics
  • translational medicine
  • genomic and multi-omics approaches to cardiovascular diseases

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

8 pages, 552 KB  
Article
Leveraging Large and Diverse Biobanks to Evaluate Gene–Disease Associations in Hypertrophic Cardiomyopathy
by Saif F. Dababneh, Kevin Ong, Darwin Yeung, Nathaniel M. Hawkins, Andrew Krahn, Zachary Laksman, Rafik Tadros and Thomas M. Roston
J. Pers. Med. 2026, 16(3), 171; https://doi.org/10.3390/jpm16030171 - 21 Mar 2026
Viewed by 1000
Abstract
Background: Hypertrophic cardiomyopathy (HCM) is a common inherited disease and a leading known cause of sudden cardiac arrest in young adults and athletes. While genetic testing has advanced rapidly in the past decade, the yield of genetic testing remains low. The Clinical Genome [...] Read more.
Background: Hypertrophic cardiomyopathy (HCM) is a common inherited disease and a leading known cause of sudden cardiac arrest in young adults and athletes. While genetic testing has advanced rapidly in the past decade, the yield of genetic testing remains low. The Clinical Genome Resource (ClinGen) initiative has become a leading resource for defining the clinical relevance of genetic variants with expert groups focusing on evaluating the strength of evidence for each HCM implicated gene. With the rise of large biobanks and population databases, genetic discovery has been significantly advanced. However, whether these databases can be used to validate gene–disease associations curated by ClinGen and provide evidence for novel gene–disease associations remains unclear. Objectives: Here, we utilized a publicly available database containing 748,879 individuals across three large biobanks (All of Us, UK biobank, Mass General Brigham biobank). Methods: We tested the association of rare coding variants in each gene in the HCM ClinGen panel with HCM. In total, 38 genes were tested, and Bonferroni correction was applied accordingly. Results: Of the 12 genes with definitive evidence for HCM (e.g., MYBPC3, MYH7, TNNT2, ALPK3), 8 (67%) demonstrated nominally significant association with HCM on a population level, and 5 (42%) remained significant after Bonferroni correction, further supporting the validity of these genes in HCM panels. Several definitive genes which are much less commonly affected in HCM (CSRP3, MYL3, ACTC1, TPM1, FHOD3, MYL2, and TNNC1) did not pass our Bonferroni corrected-significance threshold, but all had positively associated effect sizes with HCM. No genes deemed to have moderate or limited evidence had any significant associations with HCM even before Bonferroni correction. Conclusions: Altogether, we show that large biobanks and population databases generally recapitulate established gene–disease associations for HCM and support the ClinGen group’s gene curations. The utilization of such publicly accessible databases represents an additional tool for assessing gene validity in monogenic cardiac disorders with an established phenotype, although it may have limited sensitivity and should not be solely relied on. Full article
(This article belongs to the Special Issue Personalized Medicine and Surgery in Cardiovascular Disorders)
►▼ Show Figures

Figure 1

Review

Jump to: Research

18 pages, 289 KB  
Review
Single-Cell Multi-Omics Profiling of Human Septal Myectomy Tissue: Toward Precision Medicine in Obstructive Hypertrophic Cardiomyopathy
by Quynh Nguyen, Jeremy Parker, Amrit Singh, Ying Wang, Jamil Bashir and Zachary Laksman
J. Pers. Med. 2026, 16(2), 88; https://doi.org/10.3390/jpm16020088 - 4 Feb 2026
Viewed by 1128
Abstract
Hypertrophic cardiomyopathy (HCM) is an inherited cardiac disorder most commonly caused by pathogenic variants in sarcomeric genes, yet many patients remain genotype-negative and the mechanisms linking genetic alterations to disease pathology are not fully understood. Traditional bulk analyses have provided limited insight into [...] Read more.
Hypertrophic cardiomyopathy (HCM) is an inherited cardiac disorder most commonly caused by pathogenic variants in sarcomeric genes, yet many patients remain genotype-negative and the mechanisms linking genetic alterations to disease pathology are not fully understood. Traditional bulk analyses have provided limited insight into the cellular and molecular changes that drive disease progression. Recent advances in single-cell and spatial multi-omics technologies now allow detailed characterization of cell type-specific transcriptional programs, signaling pathways, and tissue remodeling within the human myocardium. These approaches have begun to redefine HCM as a complex, multicellular disease rather than a purely sarcomeric disorder. This review summarizes current single-cell and spatial transcriptomic studies of human septal myectomy tissue, outlines their major findings and limitations, and discusses how these data may inform the development of precision medicine strategies in obstructive HCM. Full article
(This article belongs to the Special Issue Personalized Medicine and Surgery in Cardiovascular Disorders)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop